2023-08-30 06:48:29 ET
More on Outlook Therapeutics
- Outlook Therapeutics: August PDUFA May Be A Buy With Some Caveats
- Outlook draws bullish views at Cantor on potential FDA nod for lead asset
- Outlook Therapeutics GAAP EPS of -$0.31 in-line
- Outlook enters definitive agreement for $31.8M convertible promissory note
- FDA accepts Outlook Therapeutics' biologics license application for wet AMD drug
- Seeking Alpha’s Quant Rating on Outlook Therapeutics
- Earnings data for Outlook Therapeutics
For further details see:
Outlook Therapeutics plunges as FDA rejects wet AMD therapy